The BCR–ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy

References

• Wendel HG, de Stanchina E, Cepero E, et al. Loss of p53 impedes the antileukemic response to BCR-ABL inhibition. Proc Natl Acad Sci USA 2006;103:7444–7449.
   PubMed Web of Science ®Google Scholar
• Makishima H, Jankowska AM, McDevitt MA, et al. CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood 2011;117:e198–e206.
   PubMed Web of Science ®Google Scholar
• Pelz-Ackermann O, Cross M, Pfeifer H, et al. Highly sensitive and quantitative detection of BCR-ABL kinase domain mutations by ligation PCR. Leukemia 2008;22:2288–2291.
   PubMed Web of Science ®Google Scholar
• Smardova J, Pavlova S, Koukalova H. Determination of optimal conditions for analysis of p53 status in leukemic cells using functional analysis of separated alleles in yeast. Pathol Oncol Res 2002;8:245–251.
   PubMedGoogle Scholar
• Fabarius A, Leitner A, Hochhaus A, et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood 2011;118:6760–6768.
   PubMed Web of Science ®Google Scholar
• Sharpless NE, DePinho RA. The INK4A/ARF locus and its two gene products. Curr Opin Genet Dev 1999;9:22–30.
   PubMed Web of Science ®Google Scholar
• Hernández-Boluda JC, Cervantes F, Colomer D, et al. Genomic p16 abnormalities in the progression of chronic myeloid leukemia into blast crisis: a sequential study in 42 patients. Exp Hematol 2003;31:204–210.
   PubMed Web of Science ®Google Scholar
• O’Shea D, O’Riain C, Gupta M, et al. Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. Blood 2009;113:2298–2301.
   PubMed Web of Science ®Google Scholar
• Nowak D, Ogawa S, Müschen M, et al. SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations. Blood 2010;115:1049–1053.
   PubMed Web of Science ®Google Scholar
• Grossmann V, Kohlmann A, Zenger M, et al. A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9%of cases. Leukemia 2011;25:557–560.
   PubMed Web of Science ®Google Scholar
• Schnittger S, Bacher U, Dicker F, et al. Associations between imatinib resistance conferring mutations and Philadelphia positive clonal cytogenetic evolution in CML. Genes Chromosomes Cancer 2010;49:910–918.
   PubMed Web of Science ®Google Scholar
• Luatti S, Castagnetti F, Marzocchi G, et al. Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. Blood 2012;120:761–767.
   PubMed Web of Science ®Google Scholar
• Meggyesi N, Kozma A, Halm G, et al. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients. Acta Haematol 2012;127:34–42.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H, Jones D, et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 2008;112:53–55.
   PubMed Web of Science ®Google Scholar
• Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003;102:276–283.
   PubMed Web of Science ®Google Scholar
• Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005;23:4100–4109.
   PubMed Web of Science ®Google Scholar
• Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041–6051.
   PubMed Web of Science ®Google Scholar
• Pavlík T, Janoušová E, Pospíšil Z, et al. Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy. BMC Med Res Methodol 2011;11:140.
   PubMed Web of Science ®Google Scholar